| Bioactivity | Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease[1][2]. |
| In Vivo | Atacicept (TACI-Ig; 100 μg; i.p.; three times of week for 14 days; BALB/c mice) reduces mature B-cell counts and serum antibody levels in normal mice[1].Atacicept (TACI-Ig) inhibits the progression of disease and autoantibody titers in a mouse model of collagen-induced arthritis (CIA)[1]. Animal Model: |
| Name | Atacicept |
| CAS | 845264-92-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302. [2]. Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9. |